{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T20:49:40Z","timestamp":1777495780405,"version":"3.51.4"},"reference-count":34,"publisher":"American Society of Hematology","issue":"26","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2016,12,29]]},"abstract":"<jats:title>Key Points<\/jats:title>\n               <jats:p>Inhibition of HDAC reverses epigenetic silencing to upregulate miRs that target BTK and suppress its downstream prosurvival signaling. We identified a rationale for the dual targeting of BTK when combined with ibrutinib and a strategy to eliminate the C481S-mutant BTK clone.<\/jats:p>","DOI":"10.1182\/blood-2016-07-727750","type":"journal-article","created":{"date-parts":[[2016,10,18]],"date-time":"2016-10-18T20:33:22Z","timestamp":1476822802000},"page":"3101-3112","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":28,"title":["Targeting BTK through microRNA in chronic lymphocytic leukemia"],"prefix":"10.1182","volume":"128","author":[{"given":"Arianna","family":"Bottoni","sequence":"first","affiliation":[{"name":"Division of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, OH;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lara","family":"Rizzotto","sequence":"additional","affiliation":[{"name":"Division of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, OH;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tzung-Huei","family":"Lai","sequence":"additional","affiliation":[{"name":"Division of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, OH;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chaomei","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX; and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lisa L.","family":"Smith","sequence":"additional","affiliation":[{"name":"Division of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, OH;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rose","family":"Mantel","sequence":"additional","affiliation":[{"name":"Division of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, OH;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sean","family":"Reiff","sequence":"additional","affiliation":[{"name":"Division of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, OH;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dalia","family":"El-Gamal","sequence":"additional","affiliation":[{"name":"Division of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, OH;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karilyn","family":"Larkin","sequence":"additional","affiliation":[{"name":"Division of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, OH;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amy J.","family":"Johnson","sequence":"additional","affiliation":[{"name":"Division of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, OH;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rosa","family":"Lapalombella","sequence":"additional","affiliation":[{"name":"Division of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, OH;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amy","family":"Lehman","sequence":"additional","affiliation":[{"name":"Center for Biostatistics, The Ohio State University, Columbus, OH"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William","family":"Plunkett","sequence":"additional","affiliation":[{"name":"Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX; and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John C.","family":"Byrd","sequence":"additional","affiliation":[{"name":"Division of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, OH;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James S.","family":"Blachly","sequence":"additional","affiliation":[{"name":"Division of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, OH;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jennifer A.","family":"Woyach","sequence":"additional","affiliation":[{"name":"Division of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, OH;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Deepa","family":"Sampath","sequence":"additional","affiliation":[{"name":"Division of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, OH;"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"234","reference":[{"issue":"8","key":"2019111612390640100_B1","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1182\/blood-2013-07-515361","article-title":"Bruton\u2019s tyrosine kinase (BTK) function is important to the development and expansion of chronic lymphocytic leukemia (CLL)","volume":"123","author":"Woyach","year":"2014","journal-title":"Blood"},{"issue":"12","key":"2019111612390640100_B2","doi-asserted-by":"crossref","first-page":"5446","DOI":"10.1182\/blood-2007-06-093906","article-title":"Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines","volume":"111","author":"Hallek","year":"2008","journal-title":"Blood"},{"issue":"1","key":"2019111612390640100_B3","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1200\/JCO.2012.44.4281","article-title":"Targeting B-Cell receptor signaling for anticancer therapy: the Bruton\u2019s tyrosine kinase inhibitor ibrutinib induces impressive responses in B-cell malignancies","volume":"31","author":"Wiestner","year":"2013","journal-title":"J Clin Oncol"},{"issue":"1","key":"2019111612390640100_B4","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1056\/NEJMoa1215637","article-title":"Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia","volume":"369","author":"Byrd","year":"2013","journal-title":"N Engl J Med"},{"issue":"1","key":"2019111612390640100_B5","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/S1470-2045(13)70513-8","article-title":"Ibrutinib as initial therapy for elderly patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: an open-label, multicentre, phase 1b\/2 trial","volume":"15","author":"O\u2019Brien","year":"2014","journal-title":"Lancet Oncol"},{"issue":"16","key":"2019111612390640100_B6","doi-asserted-by":"crossref","first-page":"2497","DOI":"10.1182\/blood-2014-10-606038","article-title":"Three-year follow-up of treatment-na\u00efve and previously treated patients with CLL and SLL receiving single-agent ibrutinib","volume":"125","author":"Byrd","year":"2015","journal-title":"Blood"},{"issue":"2","key":"2019111612390640100_B7","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1007\/s10637-015-0206-x","article-title":"Phase 1 study of the oral histone deacetylase inhibitor abexinostat in patients with Hodgkin lymphoma, non-Hodgkin lymphoma, or chronic lymphocytic leukaemia","volume":"33","author":"Morschhauser","year":"2015","journal-title":"Invest New Drugs"},{"issue":"24","key":"2019111612390640100_B8","doi-asserted-by":"crossref","first-page":"2286","DOI":"10.1056\/NEJMoa1400029","article-title":"Resistance mechanisms for the Bruton\u2019s tyrosine kinase inhibitor ibrutinib","volume":"370","author":"Woyach","year":"2014","journal-title":"N Engl J Med"},{"issue":"1","key":"2019111612390640100_B9","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1182\/blood-2015-02-626846","article-title":"Hypermorphic mutation of phospholipase C, \u03b32 acquired in ibrutinib-resistant CLL confers BTK independency upon B-cell receptor activation","volume":"126","author":"Liu","year":"2015","journal-title":"Blood"},{"issue":"1","key":"2019111612390640100_B10","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1001\/jamaoncol.2014.218","article-title":"Etiology of Ibrutinib Therapy Discontinuation and Outcomes in Patients With Chronic Lymphocytic Leukemia","volume":"1","author":"Maddocks","year":"2015","journal-title":"JAMA Oncol"},{"issue":"1","key":"2019111612390640100_B11","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1586\/17512433.2016.1096773","article-title":"Panobinostat for the treatment of relapsed or relapsed\/refractory multiple myeloma: pharmacology and clinical outcomes","volume":"9","author":"Richardson","year":"2016","journal-title":"Expert Rev Clin Pharmacol"},{"issue":"23","key":"2019111612390640100_B12","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V126.23.2935.2935","article-title":"Ibrutinib Therapy for Chronic Lymphocytic Leukemia (CLL): An Analysis of a Large Cohort of Patients Treated in Routine Clinical Practice [abstract]","volume":"126","author":"Parikh","year":"2015","journal-title":"Blood"},{"issue":"23","key":"2019111612390640100_B13","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V126.23.2945.2945","article-title":"Outcomes of Patients with Relapsed\/Refractory Chronic Lymphocytic Leukemia after Ibrutinib Discontinuation Outside Clinical Trials: A Single Institution Experience [abstract]","volume":"126","author":"Sandoval-Sus","year":"2015","journal-title":"Blood"},{"issue":"17","key":"2019111612390640100_B14","doi-asserted-by":"crossref","first-page":"6395","DOI":"10.1128\/MCB.00723-06","article-title":"Functional interplay between histone demethylase and deacetylase enzymes","volume":"26","author":"Lee","year":"2006","journal-title":"Mol Cell Biol"},{"issue":"1","key":"2019111612390640100_B15","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1172\/JCI69738","article-title":"New and emerging HDAC inhibitors for cancer treatment","volume":"124","author":"West","year":"2014","journal-title":"J Clin Invest"},{"key":"2019111612390640100_B16","author":"Balatti"},{"issue":"5","key":"2019111612390640100_B17","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1182\/blood-2011-05-351510","article-title":"Histone deacetylases mediate the silencing of miR-15a, miR-16, and miR-29b in chronic lymphocytic leukemia","volume":"119","author":"Sampath","year":"2012","journal-title":"Blood"},{"issue":"16","key":"2019111612390640100_B18","doi-asserted-by":"crossref","first-page":"3744","DOI":"10.1182\/blood-2008-09-178707","article-title":"Specific activation of microRNA106b enables the p73 apoptotic response in chronic lymphocytic leukemia by targeting the ubiquitin ligase Itch for degradation","volume":"113","author":"Sampath","year":"2009","journal-title":"Blood"},{"key":"2019111612390640100_B19","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1186\/1756-8722-2-31","article-title":"Vorinostat in solid and hematologic malignancies","volume":"2","author":"Siegel","year":"2009","journal-title":"J Hematol Oncol"},{"issue":"5","key":"2019111612390640100_B20","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1158\/1078-0432.CCR-15-0624","article-title":"A Phase I\/II Multicenter, Open-Label Study of the Oral Histone Deacetylase Inhibitor Abexinostat in Relapsed\/Refractory Lymphoma","volume":"22","author":"Evens","year":"2016","journal-title":"Clin Cancer Res"},{"issue":"8","key":"2019111612390640100_B21","doi-asserted-by":"crossref","first-page":"2221","DOI":"10.1158\/1535-7163.MCT-09-0138","article-title":"The HDAC inhibitor panobinostat (LBH589) inhibits mesothelioma and lung cancer cells in vitro and in vivo with particular efficacy for small cell lung cancer","volume":"8","author":"Crisanti","year":"2009","journal-title":"Mol Cancer Ther"},{"issue":"49","key":"2019111612390640100_B22","doi-asserted-by":"crossref","first-page":"19482","DOI":"10.1073\/pnas.0707828104","article-title":"HDAC inhibitor PCI-24781 decreases RAD51 expression and inhibits homologous recombination","volume":"104","author":"Adimoolam","year":"2007","journal-title":"Proc Natl Acad Sci USA"},{"issue":"5","key":"2019111612390640100_B23","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1158\/1535-7163.MCT-05-0442","article-title":"CRA-024781: a novel synthetic inhibitor of histone deacetylase enzymes with antitumor activity in vitro and in vivo","volume":"5","author":"Buggy","year":"2006","journal-title":"Mol Cancer Ther"},{"issue":"6","key":"2019111612390640100_B24","doi-asserted-by":"crossref","first-page":"2424","DOI":"10.1158\/0008-5472.CAN-09-0878","article-title":"Blockade of mitogen-activated protein kinase\/extracellular signal-regulated kinase kinase and murine double minute synergistically induces Apoptosis in acute myeloid leukemia via BH3-only proteins Puma and Bim","volume":"70","author":"Zhang","year":"2010","journal-title":"Cancer Res"},{"issue":"4","key":"2019111612390640100_B25","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1006\/jmcc.1998.0655","article-title":"The statistics of synergism","volume":"30","author":"Slinker","year":"1998","journal-title":"J Mol Cell Cardiol"},{"key":"2019111612390640100_B26","author":"Lagan\u00e0"},{"issue":"6","key":"2019111612390640100_B27","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1056\/NEJMoa1306220","article-title":"Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma","volume":"369","author":"Wang","year":"2013","journal-title":"N Engl J Med"},{"issue":"13","key":"2019111612390640100_B28","doi-asserted-by":"crossref","first-page":"2062","DOI":"10.1182\/blood-2014-09-603670","article-title":"Outcomes of patients with chronic lymphocytic leukemia after discontinuing ibrutinib","volume":"125","author":"Jain","year":"2015","journal-title":"Blood"},{"issue":"6","key":"2019111612390640100_B29","doi-asserted-by":"crossref","first-page":"2522","DOI":"10.4049\/jimmunol.1600915","article-title":"Functional Differences between IgM and IgD Signaling in Chronic Lymphocytic Leukemia","volume":"197","author":"Ten Hacken","year":"2016","journal-title":"J Immunol"},{"issue":"4","key":"2019111612390640100_B30","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1038\/nrc3702","article-title":"Targeting Bruton\u2019s tyrosine kinase in B cell malignancies","volume":"14","author":"Hendriks","year":"2014","journal-title":"Nat Rev Cancer"},{"issue":"23","key":"2019111612390640100_B31","doi-asserted-by":"crossref","first-page":"6287","DOI":"10.1182\/blood-2011-01-328484","article-title":"Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765","volume":"117","author":"Herman","year":"2011","journal-title":"Blood"},{"issue":"22","key":"2019111612390640100_B32","doi-asserted-by":"crossref","first-page":"6714","DOI":"10.1111\/j.1742-4658.2009.07385.x","article-title":"NF-kappaB regulates the transcription of protein tyrosine kinase Tec","volume":"276","author":"Yu","year":"2009","journal-title":"FEBS J"},{"issue":"4","key":"2019111612390640100_B33","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1111\/j.1365-2141.2009.07881.x","article-title":"Phase II study of the histone deacetylase inhibitor MGCD0103 in patients with previously treated chronic lymphocytic leukaemia","volume":"147","author":"Blum","year":"2009","journal-title":"Br J Haematol"},{"issue":"3","key":"2019111612390640100_B34","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1182\/blood-2004-05-1693","article-title":"A phase 1 and pharmacodynamic study of depsipeptide (FK228) in chronic lymphocytic leukemia and acute myeloid leukemia","volume":"105","author":"Byrd","year":"2005","journal-title":"Blood"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/128\/26\/3101\/1398132\/blood727750.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/128\/26\/3101\/1398132\/blood727750.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,16]],"date-time":"2019-11-16T17:39:23Z","timestamp":1573925963000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/128\/26\/3101\/116561\/Targeting-BTK-through-microRNA-in-chronic"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,12,29]]},"references-count":34,"journal-issue":{"issue":"26","published-print":{"date-parts":[[2016,12,29]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2016-07-727750","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,12,29]]}}}